|Biological effects of IL-21 on different immune cells and its role in autoimmune diseases|
T Gharibi, J Majidi, T Kazemi, R Dehghanzadeh, M Motallebnezhad, ...
Immunobiology 221 (2), 357-367, 2016
|miR‐142‐3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach‐1 expression|
B Mansoori, A Mohammadi, M Ghasabi, S Shirjang, R Dehghan, ...
Journal of cellular physiology 234 (6), 9816-9825, 2019
|Immunotherapeutic approaches for cancer therapy: an updated review|
T Kazemi, V Younesi, F Jadidi-Niaragh, M Yousefi
Artificial cells, nanomedicine, and biotechnology 44 (3), 769-779, 2016
|Tumor‐derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy|
C Aslan, S Maralbashi, F Salari, H Kahroba, F Sigaroodi, T Kazemi, ...
Journal of cellular physiology 234 (10), 16885-16903, 2019
|Gene therapy, early promises, subsequent problems, and recent breakthroughs|
SR Soofiyani, B Baradaran, F Lotfipour, T Kazemi, L Mohammadnejad
Advanced pharmaceutical bulletin 3 (2), 249, 2013
|Fc-fusion proteins in therapy: an updated view|
R Jafari, N M Zolbanin, H Rafatpanah, J Majidi, T Kazemi
Current medicinal chemistry 24 (12), 1228-1237, 2017
|BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes|
S Davudian, N Shajari, T Kazemi, B Mansoori, S Salehi, A Mohammadi, ...
Biomedicine & Pharmacotherapy 84, 191-198, 2016
|Circulating myeloid‐derived suppressor cells: An independent prognostic factor in patients with breast cancer|
E Safarzadeh, S Hashemzadeh, PHG Duijf, B Mansoori, V Khaze, ...
Journal of cellular physiology 234 (4), 3515-3525, 2019
|microRNA‐193a‐5p inhibits migration of human HT‐29 colon cancer cells via suppression of metastasis pathway|
N Shirafkan, N Shomali, T Kazemi, D Shanehbandi, M Ghasabi, ...
Journal of cellular biochemistry 120 (5), 8775-8783, 2019
|Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression|
N Shajari, S Davudian, T Kazemi, B Mansoori, S Salehi, ...
Artificial cells, nanomedicine, and biotechnology 46 (7), 1495-1504, 2018
|Fc receptor‐like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B‐cell chronic lymphocytic leukemia|
T Kazemi, H Asgarian‐Omran, M Hojjat‐Farsangi, M Shabani, ...
International journal of cancer 123 (9), 2113-2119, 2008
|The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasis|
M Javadian, T Gharibi, N Shekari, M Abdollahpour‐Alitappeh, ...
Journal of cellular physiology 234 (5), 5399-5412, 2019
|Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in etiology of Alzheimer?|
M Mahami-Oskouei, F Hamidi, M Talebi, M Farhoudi, AA Taheraghdam, ...
Parasitology research 115 (8), 3169-3174, 2016
|Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer|
F Asghari, N Haghnavaz, B Baradaran, M Hemmatzadeh, T Kazemi
Biomedicine & Pharmacotherapy 81, 305-317, 2016
|miR‐142‐3p is a tumor suppressor that inhibits estrogen receptor expression in ER‐positive breast cancer|
B Mansoori, A Mohammadi, MF Gjerstorff, S Shirjang, Z Asadzadeh, ...
Journal of cellular physiology 234 (9), 16043-16053, 2019
|Silencing of high mobility group isoform IC (HMGI-C) enhances paclitaxel chemosensitivity in breast adenocarcinoma cells (MDA-MB-468)|
B Mansoori, A Mohammadi, S Goldar
Advanced pharmaceutical bulletin 6 (2), 171, 2016
|Circulating microRNAs: valuable biomarkers for the diagnosis and prognosis of gastric cancer|
N Shekari, B Baradaran, D Shanehbandi, T Kazemi
Current medicinal chemistry 25 (6), 698-714, 2018
|The correlation between Toxoplasma gondii infection and Parkinson’s disease: a case-control study|
MM Oskouei, F Hamidi, M Talebi, M Farhoudi, AA Taheraghdam, ...
Journal of Parasitic Diseases 40 (3), 872-876, 2016
|Cytotoxic and apoptotic activities of methanolic subfractions of Scrophularia oxysepala against human breast cancer cell line|
M Orangi, A Pasdaran, D Shanehbandi, T Kazemi, B Yousefi, BA Hosseini, ...
Evidence-Based Complementary and Alternative Medicine 2016, 2016
|Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor|
T Kazemi, F Tahmasebi, AA Bayat, N Mohajer, J Khoshnoodi, ...
Hybridoma 30 (4), 347-353, 2011